Drugs / GSK4108771A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04762511 | Mar → May 2021 | herpes simplex infectious disease | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK4108771A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04762511 ↗ |
| Modality | Vaccine | “experimental herpes simplex virus type 2 (HSV-2) vaccine” NCT04762511 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT04762511 ↗ |